Metformina + Pioglitazona Farmoz

Metformin Hydrochloride and Pioglitazone, the active ingredients in Metformina + Pioglitazona Farmoz, are a biguanide and a thiazolidinedione presented as oral tablets for oral use. They are prescribed to improve glycemic control in adults with type 2 diabetes mellitus. GNH USA supplies Metformina + Pioglitazona Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Pioglitazona Farmoz is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Combination therapy with other antidiabetic agents: provides additive insulin‑sensitising effect. - Adjunct to diet and exercise: helps achieve target HbA1c when lifestyle measures alone are insufficient.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: increased stool frequency, usually transient. - Abdominal discomfort: bloating or cramping. - Weight gain: modest increase due to fluid retention. - Edema: peripheral swelling, especially in lower limbs. - Headache: occasional mild headache. Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Congestive heart failure: exacerbation due to fluid retention. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Bone fracture: increased risk with long‑term use. - Bladder cancer: rare association reported with pioglitazone.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Renal function: evaluate eGFR and avoid use in severe renal impairment. - Hepatic function: check liver enzymes; discontinue if significant elevation occurs. - Cardiovascular status: monitor for signs of heart failure or edema. - Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited. - Lactic acidosis risk: educate patients on recognizing symptoms and discontinue during acute illness. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Metformina + Pioglitazona Farmoz may interact with several concomitant medicines. Major Interactions (Avoid): - Known hypersensitivity to metformin or pioglitazone: contraindicated. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase pioglitazone exposure. - Iodinated contrast agents: risk of acute renal failure, temporarily discontinue metformin. Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycemia. - Loop diuretics: may exacerbate fluid retention and edema. - ACE inhibitors or ARBs: monitor renal function and potassium levels.